RT Journal Article
T1 Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
A1 Capra, Marcelo
A1 Martin, Thomas
A1 Moreau, Philippe
A1 Baker, Ross
A1 Pour, Ludek
A1 Min, Chang-Ki
A1 Leleu, Xavier
A1 Mohty, Mohamad
A1 Reinoso Segura, Marta
A1 Turgut, Mehmet
A1 LeBlanc, Richard
A1 Risse, Marie-Laure
A1 Malinge, Laure
A1 Schwab, Sandrine
A1 Dimopoulos, Meletios
K1 Low-dose dexamethasone
K1 Pooled analysis
K1 Open-label
K1 Phase-iii
K1 Lenalidomide
K1 Bortezomib
K1 Dialysis
K1 Failure
K1 Complications
K1 Reversibility
AB Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The phase III IKEMA study (clinicaltrials gov. Identifier: NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) versus Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate = 3 treatment-emergent adverse events was similar between the two arms (79.1% in Isa-Kd vs. 77.8% in Kd). In summary, the addition of Isa to Kd improved clinical outcomes with a manageable safety profile in patients with RI, consistent with the benefit observed in the overall IKEMA study population.
PB Ferrata storti foundation
SN 0390-6078
YR 2022
FD 2022-06-01
LK http://hdl.handle.net/10668/20520
UL http://hdl.handle.net/10668/20520
LA en
DS RISalud
RD Apr 10, 2025